- Financing led by Superhero Capital backed by NGL Ventures, Coinvest Capital and angel investors
- Building on strong international R&D customer base across biotech, pharma and academia
- Transforming multi-omics data into functional discoveries
- Addressing a potential USD 16 billion market
VUGENE, a Lithuania-based multi-omics data analysis company, today announced the closing an investment round of €1 million, led by Superhero Capital together with participation from NGL Ventures, Coinvest Capital and angel investors.
VUGENE will now deploy the new funds to accelerate its establishment as a global service-as-a-software company supporting researchers and industry customers worldwide by turning complex multi-omics data into functional discoveries.
VUGENE was founded in 2021 by Juozas Gordevičius with the core mission to bring together experts in biology, data and computer science to transform and advance health-related scientific research.
The ability of VUGENE’s platform to integrate biological data from all sources – transcriptomics, (epi)genomics, metabolomics, proteomics involving spatial and single-cell methods – has rapidly gained it a strong user base in academic research, which has since expanded into the industry.
Among current clients, there are well known world leading institutions: Corewell Health, Barrow Neurological Institute, Epigenetic Clock Development Foundation, RUSH University Medical Center, rAAVen Therapeutics, Biocrates.
Gražina Mykolaitytė, CEO and Co-Founder of VUGENE: “This investment serves as a confirmation that our brilliant, high-performing, and highly skilled multidisciplinary team is driving biomedical data science towards outstanding innovation. I’m truly excited that this investment will allow us to scale our innovation globally and empower our team to deliver the most accurate and comprehensive insights, helping R&D companies in the life science and biotech industries achieve their scientific discoveries. I’m incredibly proud of our team and company founder Juozas Gordevicius, for living and sharing his vision with all of us.”
Juozas Gordevičius, Founder of VUGENE, commented: “VUGENE analysis integrates data from multiple omics experiments, providing a comprehensive characterization of biological systems. This enables our customers to discover therapeutic targets, understand disease mechanisms, and develop advanced, more personalized diagnostic solutions. Already we are seeing many of them making exciting discoveries in a wide range of fields – Neurodegeneration, Cancer, Gene Therapy, Microbial Genomics, Cardiovascular disorders. We are therefore delighted to have attracted support from this syndicate of high-quality, experienced investors to fund our continued growth and expansion.”
Gytenis Galkis, Partner at Superhero Capital, said: “We are proud to lead this competitive investment round in Vugene, a company that’s uniquely positioned to make a significant impact in biological research by turning complex multi-omics data into actionable insights. Juozas Gordevičius and Gražina Mykolaitytė embody the visionary spirit and disciplined execution we admire at Superhero Capital, both in their entrepreneurial journey and their shared passion for sailing—an activity that mirrors the precision, teamwork, and resilience they’ve demonstrated in navigating the competitive waters of biotech innovation. With their strong international R&D foundation and exceptional multidisciplinary team, we believe Vugene is poised to become a global leader in biotech data analytics.”
Justinas Pašys, CEO of NGL Ventures, added: “VUGENE is addressing a fundamental bottleneck in biomedical research by automating complex biological data interpretation. The startup’s strong commercial traction, exceptional team, and proprietary technology position them well to continue its growth and become a category leader in a rapidly growing market. We are excited to back VUGENE as they scale their product globally and help accelerate scientific discoveries across biotech and pharma.”
Cover photo credits: Andrej Vasilenko
Photo credits: Andrej Vasilenko